News

PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from a Phase 2a clinical trial. Given these results, developer NeuroSense Therapeutics will continue investigating PrimeC with additional analysis…

Study Describes New Compounds With Potential to Treat ALS

Newly developed compounds derived from ebselen could be used to treat some types of amyotrophic lateral sclerosis (ALS), a recent study suggests. The study, “Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis,” was published in EBioMedicine. About a fifth of familial…